The implantable cardiac defibrillator (ICD) market may be poised to rebound from the black eye it has suffered following recalls and recent lead malfunctions, based on news from the REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction (REVERSE) trial –- intended to establish that patients with mild heart failure may benefit from cardiac resynchronization therapy (CRT).